Delays in drug approvals value pharmaceutical companies cash. These prices embrace each misplaced gross sales in addition to extra value if medical trials must span an extended period. Whereas these details usually are not unsure, a key query is how a lot do delays in approval value companies?
A paper by Smith, DiMasi and Getz (2024) gives the reply.
…a single day equals roughly $500,000 in misplaced prescription drug or biologic gross sales, with day by day prescription gross sales for infectious, hematologic, cardiovascular, and gastrointestinal ailments among the many highest…The estimated direct day by day value to conduct a medical trial is roughly $40,000 per day for part II and III medical trials, with these in respiratory, rheumatology, and dermatology having the best relative day by day direct prices.
About 60% of medicine had been first launched within the US. About 37.7% of medicine had been “blockbuster” medication with greater than $1m of gross sales per day; 3.1% of medicine had >$7m of gross sales per day.
Cardiovascular, hematology, an infection and oncology medication had the best gross sales per day primarily based on median gross sales per day.
The common medical trial value $25 million and took 614.8 days to finish. As anticipated, later stage medical trials are costlier:
… part III medical trials have the best day by day value at $55,716. Section II medical trials value roughly half that quantity at $23,737 per day (confer with Desk 8). Section IV and part I trials have the bottom day by day value at $14,091 and $7,829 per day, respectively.
Strategies
rug income information got here from Cortellis database of drug gross sales for all medication and biologics launched in 2000 or after. These information comprise worldwide gross sales figures from firm annual reviews. As drug gross sales information had been extremely right-skewed the authors eliminated (i) COVID-19 medication and vaccines and (ii) any medication with gross sales >2 customary deviations from the imply
Drug growth prices per day had been estimated from a proprietary dataset developed and maintained by Tufts College’s Heart for the Research of Drug Growth (CSDD).